NANOPARTICLES INCLUDING A GLATIRAMOID USEFUL IN POLYNUCLEOTIDE DELIVERY

Abstract

The present technology is directed to composition that may be formulated for parenteral administration, where the composition includes a plurality of nanoparticles and optionally a pharmaceutically acceptable carrier. Each nanoparticle of the plurality includes a glatiramoid and one or more of a polyinosine-polycytidylic acid (Poly(I:C)), a plasmid DNA (pDNA), a CpG oligodeoxynucleotide (CpG ODN), or a combination of any two or more thereof.

Description

Claims

1. A composition comprising a plurality of nanoparticles, each nanoparticle of the plurality of nanoparticles comprising a glatiramoid; andone or more polynucleotides comprising a polyinosine-polycytidylic acid (Poly(I:C)), a plasmid DNA (pDNA), a CpG oligodeoxynucleotide (CpG ODN),or a combination of any two or more thereof.

2. The composition of claim 1, wherein the nanoparticles are configured to possess a ratio of cationic charges of the glatiramoid (N) to phosphate anionic charges of polynucleotide (P) of about 0.5:1 to about 100:1.

3. The composition of claim 1, wherein the nanoparticles are configured to possess a mass ratio of glatiramoid to polynucleotide of about 0.5:1 to about 30:1.

4. The composition of claim 1, wherein the Poly(I:C) has a weight average number of base pairs of about 0.2 kb to about 8 kb.

5. The composition of claim 1, wherein the CpG ODN comprises a Class A CpG ODN, a Class B CpG ODN, a Class C CpG ODN, or a combination of any two or more thereof.

6. The composition of claim 1, wherein the CpG ODN comprises Class B CpG ODN 1825, Class B CpG ODN 2006, Class B CpG ODN BW006, Class B CpG ODN 1668, Class A CpG ODN 1585, Class A CpG ODN 2216, Class A CpG ODN 2336, Class C CpG ODN 2395, Class C CpG ODN M362, or a combination of any two or more thereof.

7. The composition of claim 1, wherein the pDNA comprises angiotensin II type 2 receptor pDNA, pDNA encoding anti-HER2 antibody, pDNA encoding murine interferon α, or a combination of any two or more thereof.

8. The composition of claim 1, wherein the glatiramoid has a weight average molecular weight of about 5,000 to about 18,000.

9. The composition of claim 1, wherein the glatiramoid comprises glatiramer acetate (GA), protirmamer, or both.

10. The composition of claim 1, wherein the nanoparticles have an intensity-weighted average diameter as determined by dynamic light scattering of about 20 nm to about 500.

11. The composition of claim 1,wherein the composition further comprises a pharmaceutically acceptable carrier.

12. The composition of claim 1, wherein the composition further comprises water.

13. The composition of claim 1, wherein the composition is formulated for parenteral administration.

14. The composition of claim 11, wherein the composition is at a pH of about 5 to about 10.

15. The composition of claim 14, wherein the composition comprises CaCl2 at a concentration no greater than about 1 mM.

16. The composition of claim 14, wherein the composition comprises CaCl2 at a concentration no greater than about 1 nanomolar.

17. A method for delivering a polyinosine-polycytidylic acid (Poly(I:C)), a plasmid DNA (pDNA), a CpG oligodeoxynucleotide (CpG ODN), or a combination of any two or more thereof, to a subject, the method comprising administering a composition of claim 1 to the subject.

18. The method of claim 17, wherein the nanoparticles are configured to possess a ratio of cationic charges of the glatiramoid (N) to phosphate anionic charges of polynucleotide (P) of about 0.5:1 to about 100:1.

19. The method of claim 17, wherein the nanoparticles are configured to possess a mass ratio of glatiramoid to polynucleotide of about 0.5:1 to about 30:1.

20. The method of claim 17, wherein the Poly(I:C) has a weight average number of base pairs of about 0.2 kb to about 8 kb.